Intima Bioscience, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
2
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)CISH Inactivated TILs in the Treatment of NSCLC
Phase 1
Not yet recruiting
- Conditions
- Metastatic Non Small Cell Lung CancerStage IV Non-small Cell Lung CancerSquamous Cell Lung CancerCarcinoma, Non-Small-Cell LungAdenocarcinoma of LungLarge Cell Lung Cancer
- Interventions
- Biological: CISH Inactivated TIL
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Intima Bioscience, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05566223
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
Phase 1
Active, not recruiting
- Conditions
- Cancer, GastrointestinalGall Bladder CancerStomach CancerGastrointestinal Epithelial CancerGastrointestinal NeoplasmsCancer of Gastrointestinal TractGastrointestinal CancerPancreatic CancerColo-rectal CancerColon Cancer
- Interventions
- Biological: Tumor-Infiltrating Lymphocytes (TIL)
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Intima Bioscience, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04426669
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
News
No news found